[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,479,078
  • Shares Outstanding, K 168,652
  • Annual Sales, $ 68,560 K
  • Annual Income, $ -437,990 K
  • EBIT $ -479 M
  • EBITDA $ -458 M
  • 60-Month Beta 1.65
  • Price/Sales 21.50
  • Price/Cash Flow N/A
  • Price/Book 1.87

Options Overview Details

View History
  • Implied Volatility 81.17% (+8.40%)
  • Historical Volatility 48.53%
  • IV Percentile 33%
  • IV Rank 6.38%
  • IV High 520.93% on 11/04/25
  • IV Low 51.19% on 07/31/25
  • Expected Move (DTE 14) 0.47 (5.33%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 130
  • Volume Avg (30-Day) 321
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 10,180
  • Open Int (30-Day) 9,992
  • Expected Range 8.30 to 9.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.44
  • Number of Estimates 4
  • High Estimate $1.45
  • Low Estimate $-0.71
  • Prior Year $-0.80
  • Growth Rate Est. (year over year) +155.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.52 +2.93%
on 05/19/26
10.45 -16.08%
on 05/05/26
-1.23 (-12.30%)
since 05/01/26
3-Month
8.26 +6.17%
on 03/30/26
11.66 -24.79%
on 04/20/26
-0.14 (-1.57%)
since 03/03/26
52-Week
4.16 +111.07%
on 08/11/25
11.66 -24.79%
on 04/20/26
+3.54 (+67.69%)
since 06/03/25

Most Recent Stories

More News
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in “Best of EASL 2026” by EASL - Poster...

VIR : 8.77 (+0.34%)
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN ® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion...

VIR : 8.77 (+0.34%)
Can Vir Biotechnology's Hepatitis Pipeline Finally Justify the Astellas Collaboration Premium?

Barchart Research What to Expect from VIR Earnings VIR Generated May 5, 2026 Current Price $10.01 EPS Estimate $$-0.01 Consensus Rating Strong Buy Average Move 13.11% Can Vir Biotechnology's Hepatitis...

VIR : 8.77 (+0.34%)
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare...

VIR : 8.77 (+0.34%)
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results...

VIR : 8.77 (+0.34%)
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization of VIR-5500...

VIR : 8.77 (+0.34%)
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive...

VIR : 8.77 (+0.34%)
Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: ...

VIR : 8.77 (+0.34%)
Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...

VIR : 8.77 (+0.34%)
Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...

VIR : 8.77 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 9.32
2nd Resistance Point 9.18
1st Resistance Point 8.97
Last Price 8.77
1st Support Level 8.62
2nd Support Level 8.48
3rd Support Level 8.27

See More

52-Week High 11.66
Fibonacci 61.8% 8.79
Last Price 8.77
Fibonacci 50% 7.91
Fibonacci 38.2% 7.02
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.